InVitria and Cellevate Partner on Vaccine Manufacturing

Published on 12 March 2026

Partnership explores upstream bioprocessing approaches for scalable viral vaccine production

InVitria has entered a strategic collaboration with Cellevate AB to explore improved upstream solutions for viral vaccine production.

The collaboration brings together Cellevate’s Cellevat3d® nanofiber microcarrier platform with InVitria’s chemically defined recombinant proteins to support scalable, animal-origin-free vaccine manufacturing workflows.

Cellevat3d enables high-density adherent cell culture, while InVitria’s recombinant media components help provide consistent and defined culture conditions for biomanufacturing.

Together, these technologies aim to support developers of viral vaccines and viral vector-based therapeutics.

Read the full announcement from Cellevate: